EUVIMEDEUVIMED entdecken
Kohortenstudie

Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study

Louise Ladebo iD, Martin T Ernst iD, Aurélie Mailhac iD, Carsten Dirksen iD, Kirstine N Bojsen-Møller iD, Anton Pottegård iD

Diabetes Care · 2024

DOI: 10.2337/dc24-1082 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes Care, 2024. Verfasst von Louise Ladebo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To determine patient characteristics and dose titration patterns of real-world semaglutide (Wegovy) users. RESEARCH DESIGN AND METHODS We used a population-based cohort study including Danish adults who filled semaglutide prescriptions from 12 December 2022 to 31 December 2023. Outcomes were patient characteristics, prescriber type, and dose titration patterns. RESULTS We identified 110,748 individuals (median age 49 years; 70% female) filling 773,708 prescriptions for semaglutide. General practitioners initiated treatment in 86%. Common comorbidities included hypertension (30%), dyslipidemia (17%), and arthrosis (17%). Only 13% reached the maximum dose of 2.4 mg by their fifth prescription, while 5.7% stopped after the first prescription. Few users (10%) followed recommended dose increases every 4 weeks. Overall, 25% filled at least one prescription of 2.4 mg, while 33–48% continued with the 1.0-mg dosage from the fourth prescription onward. CONCLUSIONS Real-world semaglutide users generally resembled trial participants, but few follow the dose titration schemes tested in premarket clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesHypoglycemic AgentsHumansFemaleMiddle AgedMaleCohort StudiesAdultDenmarkAgedSemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
  • Department of Respiratory Diseases and Endocrinology, Copenhagen University Hospital - Hvidovre, Hvidovre, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Louise Ladebo, Martin T Ernst, Aurélie Mailhac, Carsten Dirksen, Kirstine N Bojsen-Møller, Anton Pottegård

Zitieren

APA

Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024). Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study. Diabetes Care. https://doi.org/10.2337/dc24-1082

Vancouver

Ladebo L, Ernst MT, Mailhac A, Dirksen C, Bojsen-Møller KN, Pottegård A. Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study. Diabetes Care. 2024. doi:10.2337/dc24-1082

BibTeX
@article{Ladebo2024,
  author = {Ladebo, Louise and Ernst, Martin T and Mailhac, Aurélie and Dirksen, Carsten and Bojsen-Møller, Kirstine N and Pottegård, Anton},
  title = {Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc24-1082}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche